These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26759625)

  • 1. Economic implications of biological therapy for Crohn's disease.
    Petryszyn PW; Paradowski L
    Prz Gastroenterol; 2015; 10(4):197-202. PubMed ID: 26759625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of illness of Crohn's disease.
    Bodger K
    Pharmacoeconomics; 2002; 20(10):639-52. PubMed ID: 12162753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic implications of biological therapies for Crohn's disease: review of infliximab.
    Bodger K
    Pharmacoeconomics; 2005; 23(9):875-88. PubMed ID: 16153132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost of Crohn's disease: drugs or surgery?
    Cohen RD
    BioDrugs; 2000 Nov; 14(5):331-44. PubMed ID: 18034577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance of remission in Crohn's disease: current and emerging therapeutic options.
    Brookes MJ; Green JR
    Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in the treatment strategy for pediatric Crohn's disease.
    Kim MJ; Choe YH
    Korean J Pediatr; 2010 Sep; 53(9):830-3. PubMed ID: 21189967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.
    Sprakes MB; Ford AC; Suares NC; Warren L; Greer D; Donnellan CF; Jennings JS; Everett SM; Hamlin PJ
    Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1357-63. PubMed ID: 21050238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
    Aliyev ER; Hay JW; Hwang C
    Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
    Orlando A; Colombo E; Kohn A; Biancone L; Rizzello F; Viscido A; Sostegni R; Benazzato L; Castiglione F; Papi C; Meucci G; Riegler G; Mocciaro F; Cassinotti A; Cosintino R; Geremia A; Morselli C; Angelucci E; Lavagna A; Rispo A; Bossa F; Scimeca D; Cottone M;
    Dig Liver Dis; 2005 Aug; 37(8):577-83. PubMed ID: 15886081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.
    Tang DH; Armstrong EP; Lee JK
    Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada.
    Panaccione R;
    Can J Gastroenterol; 2001 Jun; 15(6):371-5. PubMed ID: 11429666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N; Townsend CM; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD000545. PubMed ID: 27783843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N; Tsoulis DJ; MacDonald JK
    Cochrane Database Syst Rev; 2013 Apr; (4):CD000545. PubMed ID: 23633304
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.